Oaklins



Arjen Kostelijk, Oaklins' testing, inspection & certification (TIC) specialist, is pleased to share an update on M&A in the sector in this third edition of Spot On.


"Oaklins has advised on numerous mergers and acquisitions in the TIC sector. Recent examples include the sales of CAG AMned to Gate Invest, Genesis Group to Actis, Omegam Laboratoria to Eurofins, Roos+Bijl to

SGS and Tem Group to Instrumentation Laboratory. Private equity (PE) firms have been very active in the TIC industry and, in the last five years, we have seen a clear increase in deal activity involving private equity.

This newsletter provides further insight into the current active role of private equity investors in the TIC M&A market, covering the subjects below."







VALUATION METRICS

15.2x

14.9x

17.5x

17.9x

16.0x

11.3x

11.3x

11.3x

11.3x

11.3x

11.3x

11.3x

12.2x

11.3x

11.3x

12.2x

11.3x

12.2x

13.4x

13.4x

13.3x

13.4x

13.3x

13.4x

13.3x

13.4x

13.4

Page 6


Market trends

Private equity becomes increasingly active in the TIC M&A market

The global M&A market is still booming, thanks in part to ongoing economic prosperity, the wider availability of low-cost and flexible financial debt, and the growing presence of private equity funds seeking profitable investments.

In the past five years we have seen increasing activity from private equity firms in the TIC sector, largely due to the extremely strong and resilient industry fundamentals that make this a popular sector for financial investors.

Number of deals involving private equity (global TIC deals from 2013 to 2017)



Source: Mergermarket

TIC companies generally deliver high margins combined with relatively low capital expenditure. In addition, their financial performance is often underpinned by significant revenue visibility, coming from long-term contracts supported by increasing regulation. Another of the sector's key attractions is the potential for multiple exit options, including secondary buy-outs, IPOs or a sale to one of the very acquisitive trade buyers, such as Eurofins (39 deals in 2017 and 2018), SGS (eight deals) or Bureau Veritas (10 deals).

Private equity groups are responsible for many notable transactions in the sector. Financial investors own around 70% of all TIC companies with revenues between US\$50 million and US\$1 billion. Recent examples include Apax's acquisition of the remaining stake in Unilabs (11.8x EV/EBITDA),

PSP's and Partners Group's investment in Cerba Healthcare (12.0x EV/EBITDA) and Bridgepoint's acquisition of Element Materials Technology (11.3x EV/EBITDA).

Private equity investors tend to aggressively look for buy-and-build projects in the mid-market in order to build sector leadership with a strategic geographic footprint. By actively pursuing buy-andbuild strategies, financial investors can increase the efficiency and occupancy rates of their portfolio companies. In addition, multiple arbitrage can be achieved when growing a business above certain thresholds. As the TIC sector is still fragmented, there are ample opportunities for private equity firms to further build their TIC platforms with strategic acquisitions, thereby boosting their return on investments.

Spotlight

Recent private equity platform acquisitions and their buy-and-build programs





In January 2017, Switzerland-based private equity firm Partners Group and Canadian state-owned pension investment firm PSP acquired Cerba Healthcare, a France-based operator of clinical pathology laboratories, for a total consideration of US\$1,920 million. After the transaction, the Cerba platform is further strengthened with the acquisitions of:

Date	Target	Country	Target description
29 Mar 2018	Н⁵Ёт⊟∟іጣ		Provider of histology services, including histology, immunohistochemistry, in situ hybridization and image analysis
28-Jul-2017	GROUPEBIO7		Owner and operator of clinical pathology laboratories
28-Jul-2017	FLEMING RESEARCH		Provider of diagnostic services
6-Feb-2107	deltamedica		Provider of clinical analysis services and diagnostic services






In December 2016, UK-based private equity firm Apax Partners acquired Unilabs, a Switzerland-based diagnostics company engaged in the provision of laboratory medicine and radiology services, for a total consideration of US\$1,588 million. After the transaction, Unilabs made several add-on acquisitions, of which a selection is listed below:

Date	Target	Country	Target description
1-Jun-2018	Medi tert	•	Operator of specialized medical laboratories
25-Mar-2018	TMC		Provider of teleradiology and telepathology services
7-Oct-2017	MEDL ON MEDISCHE BIAGNOSTIEK		Provider of services in the field of clinical chemistry diagnostics
9-Feb-2017	ALPHA MEDICAL	(Provider of laboratory testing and diagnostic services

Spotlight

16-Jan-2017

Recent private equity platform acquisitions and their buy-and-build programs



Provider of testing services for the aerospace sector



Introduction to private equity deals

Insights

When selling a company, a rough split can be made between two types of buyers:

- strategic buyers
- financial buyers, including private equity firms, family offices and high-net-worth individuals.


Both buyer groups have their own characteristics, advantages and disadvantages. As this newsletter is focused on the role of private equity in the TIC sector, we will give a short introduction to private equity investors, their added value and the typical transaction structures they work with.

Private equity investors can offer significant added value for private company owners to consider. Firstly, financial investors manage large funds of money, from which they can offer growth capital to support their portfolio companies in a next phase of growth. Financial investors can also be seen as serious sparring partners, offering the relevant expertise to support organic and acquisitive growth. In addition, selling your business to a private equity firm provides an opportunity for the selling shareholders to roll over retained equity and benefit from a second exit.

Transactions involving private equity investors are often characterized as leveraged buy-outs (LBOs). An LBO is the acquisition of a company by a financial investor using equity and a significant amount of borrowed money (leverage) to meet the cost of acquisition. The opportunity for private equity firms to lever a large part of their acquisitions with external debt enables them to win acquisitions with premium valuations without hurting their internal rate of return hurdles.

We see an ongoing eagerness among banks and debt funds to finance these types of acquisitions, particularly when strong, renowned private equity firms with longterm track records are involved. Financing multiples depend on many factors, such as the industry, business plan, stability of cash flows and deal size. Please see below the development of financing multiples for mid-market LBO deals.

Financing multiples for mid-market LBO deals



Source: Dealogic




Valuation trends

Continued high valuations for TIC companies

Valuations for listed TIC companies have risen, on average, by circa 81.9% since the beginning of January 2015 (compared with 29.3% for the STOXX Global 1800). The ongoing high valuations for TIC companies are partially driven by ongoing consolidation in the market as well as overall favorable market trends.

The EV/EBITDA median for the selected peer group in 2017 and 2018E is 15.2x and 13.3x, respectively. These high valuations provide ample room for multiple arbitrage for consolidators aiming to sell to large industry players.

EV/EBITDA multiples (as of 15 July 2018)



Source: Infinancials



Arjen Kostelijk, TIC Specialist, Oaklins

"We believe the intention to be a one-stop shop for clients, along with a determination to be more cost efficient and the need to adhere to stricter industry regulations, will continue to be key drivers behind consolidation in the TIC market. As a result, we expect valuations to rise, and we are confident that certain macro-economic trends — including the ample availability of funds and private equity's insatiable need to invest — will ensure continued momentum in the M&A market."



Valuation trends

An overview of selected M&A transactions with PE involvement on the buy-side

Date	Target	Buyer	Country	PE-backing by	Rationale	Valuation		
						EV (US\$)	EV/ Sales¹	EV/ EBITDA
1-Jun-2018	Medi test	Unilabs	O / O	Apax	Switzerland-based operator of specialized medical laboratories	N/A	N/A	N/A
29-May-2018	HAMILTON	MIDEUROPA			Poland-based company engaged in providing laboratory inspection and testing services for various industries	N/A	N/A	N/A
29-May-2018	WEST PHYSICS The Medical Physics Experts	LNC			Poland-based company engaged in providing laboratory inspection and testing services for various industries	N/A	N/A	N/A
24-May-2018	CARE FOR FOOD GROUP	Normec		SUMMIT PARTNERS	Netherlands-based company that provides solutions in the field of quality and food safety, including process control quality, laboratory research, QA automation, training and label control	N/A	N/A	N/A
23-May-2018	PROA	TEMASEK			Mexico-based operator of clinical diagnostic laboratories	N/A	N/A	N/A
3-Apr-2018	VRO Certification	Normec	%	SUMMIT PARTNERS	Netherlands-based company engaged in inspection and examination of various certifications	N/A	N/A	N/A
23-Mar-2018	GROUPEBIO7	Cerba Health/Care	%	Partners Group	France-based company that owns and operates clinical pathology laboratories	555.4	4.5x	N/A
1-Mar-2018	enitial	COWOOD		ınflexion	UK-based provider of emission and pollution monitoring, control and management services	N/A	N/A	N/A
2-Nov-2017	A+métrologie	Trescal	%	ARDIAN	France-based company engaged in providing calibrations and multisize checks, 3D measurements, maintenance, fleet management, training, consulting, pre-audits and non-destructive testing services	N/A	N/A	N/A
7-Oct-2017	MEDLON MEDISCHE BRAGNOSTIEN	Unilabs	%	Apax	Netherlands-based laboratory that offers services in the field of clinical chemistry diagnostics to primary and secondary care providers	N/A	N/A	N/A
24-Aug-2017	FLEXRAY				US-based provider of testing, inspection and recovery services for food industry	N/A	N/A	N/A
7-Aug-2017	SCGC genetics	Unilabs		Apax	Portugal-based company engaged in providing specialty genetic tests and operating a clinical laboratory	N/A	N/A	N/A
21-Jul-2017	Y RKTEST' LABORATORIES	KCP			UK-based food intolerance testing company	N/A	N/A	N/A
29-Jun-2017	Exova 🏢	element		Bridgepoint	UK-based laboratory testing provider	979.3	2.3x	11.8x

Source: Mergermarket. Note 1: Based on historical values



M&A activity

Selected Oaklins TIC transactions


































About Oaklins

MEET OAKLINS, THE WORLD'S MOST EXPERIENCED MID-MARKET M&A ADVISOR











Oaklins offers a comprehensive range of services

- M&A advisory (buy- and sell-side)
- Growth equity and equity capital markets advisory
- Debt advisory
- Corporate finance services

Oaklins industry specialists

Testing, inspection & certification is one of our focus areas. Combining comprehensive sector knowledge with global execution has led Oaklins to become the most experienced M&A advisor in the TIC sector, with a large contact network of the most relevant market players worldwide. This results in the best possible merger, acquisition and divestment opportunities for TIC companies.

If mergers, acquisitions or divestitures of businesses or business units are part of your strategy, we would welcome the opportunity to exchange ideas with you. Please find our contact details below.



Arjen Kostelijk, Partner Amsterdam, Netherlands M: +31 6 13979718



Jan P. Hatje, Managing Partner Hamburg, Germany T: +49 40 34914175




Jean-Patrick Larivière, Managing Partner Montreal, Canada

T: +1 514-954-0070 x524



Maarten Wolleswinkel, Partner Amsterdam, Netherlands M: +31 6 5367 9442

Oaklins - our offices around the world



Disclaimer

This document is provided for information purposes only. Oaklins and its member firms make no guarantee, representation or warranty of any kind regarding the timeliness, accuracy or completeness of its content. This document is not intended to convey investment advice or solicit investments of any kind whatsoever. No investment decisions should be taken based on the content and views expressed herein. Oaklins and its member firms shall not be responsible for any loss sustained by any person who relies on this publication.

© 2018 All rights reserved.

Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.

